Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XJ101
- Development stage
- Phase 1
- Lead developer
- Starmab Biologics
- Administration
- Intravenous
01
Overview
XJ101 is an investigational drug developed for the treatment of infectious diseases, with a primary focus on Staphylococcus aureus infections and sepsis. It is being evaluated as an intravenous formulation in early-phase clinical trials to assess its safety, tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics (PD) in healthy volunteers. The precise mechanism of action has not been disclosed publicly. The drug is under development by Xingji Biology (Suzhou) Co., Ltd and has also been associated with Starmab Biologics (Shanghai) Co., Ltd[2][3][5]. As of June 2025, it has not received regulatory approval in any country.
Beyond the preview
Go deeper on XJ101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XJ101.